JP2021500895A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500895A5 JP2021500895A5 JP2020523427A JP2020523427A JP2021500895A5 JP 2021500895 A5 JP2021500895 A5 JP 2021500895A5 JP 2020523427 A JP2020523427 A JP 2020523427A JP 2020523427 A JP2020523427 A JP 2020523427A JP 2021500895 A5 JP2021500895 A5 JP 2021500895A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- sequence
- acid sequence
- alk7
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 240
- 102100034135 Activin receptor type-1C Human genes 0.000 claims description 139
- 101710173005 Activin receptor type-1C Proteins 0.000 claims description 139
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 18
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 239000003446 ligand Substances 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 12
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 12
- 102000005962 receptors Human genes 0.000 claims description 10
- 108020003175 receptors Proteins 0.000 claims description 10
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 claims description 9
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 claims description 9
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 9
- 101000893552 Homo sapiens Embryonic growth/differentiation factor 1 Proteins 0.000 claims description 9
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 claims description 9
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 108010023079 activin B Proteins 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 210000000577 adipose tissue Anatomy 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 208000017169 kidney disease Diseases 0.000 claims description 8
- 208000019423 liver disease Diseases 0.000 claims description 8
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 8
- 208000004611 Abdominal Obesity Diseases 0.000 claims description 7
- 108010059616 Activins Proteins 0.000 claims description 7
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 7
- 208000034578 Multiple myelomas Diseases 0.000 claims description 7
- 239000000488 activin Substances 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 6
- 230000005856 abnormality Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010065941 Central obesity Diseases 0.000 claims description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 208000018565 Hemochromatosis Diseases 0.000 claims description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 102000004895 Lipoproteins Human genes 0.000 claims description 4
- 108090001030 Lipoproteins Proteins 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010033307 Overweight Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 4
- 208000007452 Plasmacytoma Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000008694 endothelial dysfunction Effects 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 201000001421 hyperglycemia Diseases 0.000 claims description 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 4
- 201000008980 hyperinsulinism Diseases 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000018191 liver inflammation Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 230000026731 phosphorylation Effects 0.000 claims description 4
- 238000006366 phosphorylation reaction Methods 0.000 claims description 4
- 201000004193 respiratory failure Diseases 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 229940116269 uric acid Drugs 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 206010022979 Iron excess Diseases 0.000 claims description 3
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 3
- 230000003187 abdominal effect Effects 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000004807 localization Effects 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims description 2
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 claims description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 230000003042 antagnostic effect Effects 0.000 claims description 2
- 102000023732 binding proteins Human genes 0.000 claims description 2
- 108091008324 binding proteins Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- -1 co-receptor (e.g. Proteins 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 description 27
- 238000012217 deletion Methods 0.000 description 26
- 230000037430 deletion Effects 0.000 description 26
- 238000003780 insertion Methods 0.000 description 26
- 230000037431 insertion Effects 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 13
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 8
- 230000004130 lipolysis Effects 0.000 description 8
- 210000001789 adipocyte Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000001593 brown adipocyte Anatomy 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000636 white adipocyte Anatomy 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023192144A JP2024023278A (ja) | 2017-10-25 | 2023-11-10 | Ａｌｋ７結合タンパク質およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577038P | 2017-10-25 | 2017-10-25 | |
| US62/577,038 | 2017-10-25 | ||
| PCT/US2018/057482 WO2019084249A1 (en) | 2017-10-25 | 2018-10-25 | ALK7 BINDING PROTEINS AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192144A Division JP2024023278A (ja) | 2017-10-25 | 2023-11-10 | Ａｌｋ７結合タンパク質およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500895A JP2021500895A (ja) | 2021-01-14 |
| JP2021500895A5 true JP2021500895A5 (enExample) | 2021-12-02 |
| JP7433222B2 JP7433222B2 (ja) | 2024-02-19 |
Family
ID=66246796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523427A Active JP7433222B2 (ja) | 2017-10-25 | 2018-10-25 | Ａｌｋ７結合タンパク質およびその使用 |
| JP2023192144A Withdrawn JP2024023278A (ja) | 2017-10-25 | 2023-11-10 | Ａｌｋ７結合タンパク質およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192144A Withdrawn JP2024023278A (ja) | 2017-10-25 | 2023-11-10 | Ａｌｋ７結合タンパク質およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11981738B2 (enExample) |
| EP (1) | EP3700571A4 (enExample) |
| JP (2) | JP7433222B2 (enExample) |
| KR (1) | KR20200089666A (enExample) |
| CN (1) | CN111836642A (enExample) |
| AU (1) | AU2018354295B2 (enExample) |
| BR (1) | BR112020007751A2 (enExample) |
| CA (1) | CA3079963A1 (enExample) |
| WO (1) | WO2019084249A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220080015A (ko) | 2016-04-22 | 2022-06-14 | 악셀레론 파마 인코포레이티드 | Alk7 결합 단백질 및 이들의 용도 |
| WO2019084249A1 (en) | 2017-10-25 | 2019-05-02 | Acceleron Pharma Inc. | ALK7 BINDING PROTEINS AND USES THEREOF |
| CA3142147A1 (en) * | 2019-05-30 | 2020-12-03 | Acceleron Pharma Inc. | Alk7 binding proteins and uses thereof |
| JP7541709B2 (ja) * | 2020-03-19 | 2024-08-29 | 株式会社CUBICStars | タンパク質結合部位情報取得装置、タンパク質結合部位情報取得装置の作動方法及びプログラム |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614609A (en) * | 1994-10-20 | 1997-03-25 | Carlos F. Ibanez | Serine threonine kinase receptor |
| WO1998055619A1 (de) | 1997-06-06 | 1998-12-10 | Asat Ag Applied Science & Technology | Anti-gpiib/iiia rekombinante antikörper |
| CN103554260A (zh) | 2005-10-12 | 2014-02-05 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| CN104174025B (zh) | 2008-12-05 | 2017-01-11 | 阿布拉西斯生物科学有限责任公司 | Sparc结合肽及其应用 |
| BR112016014163A2 (pt) | 2013-12-19 | 2018-01-09 | Arsanis Biosciences Gmbh | anticorpos direcionados contra a toxina lukgh (lukab) de staphylococcus aureus e as sequências de anticorpos, seu uso no tratamento ou no diagnóstico de infecção por s. aureus, as preparações farmacêuticas e para diagnóstico, os ácidos nucleicos que codificam os anticorpos, o paratopo isolado dos anticorpos e o epítopo conformacional isolado |
| KR101644043B1 (ko) | 2014-03-18 | 2016-08-01 | 한국과학기술원 | Ｒｎａ에 특이적으로 결합하는 항체 |
| WO2017177013A1 (en) | 2016-04-06 | 2017-10-12 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| KR20220080015A (ko) | 2016-04-22 | 2022-06-14 | 악셀레론 파마 인코포레이티드 | Alk7 결합 단백질 및 이들의 용도 |
| WO2019084249A1 (en) | 2017-10-25 | 2019-05-02 | Acceleron Pharma Inc. | ALK7 BINDING PROTEINS AND USES THEREOF |
-
2018
- 2018-10-25 WO PCT/US2018/057482 patent/WO2019084249A1/en not_active Ceased
- 2018-10-25 KR KR1020207013832A patent/KR20200089666A/ko not_active Ceased
- 2018-10-25 AU AU2018354295A patent/AU2018354295B2/en active Active
- 2018-10-25 CA CA3079963A patent/CA3079963A1/en active Pending
- 2018-10-25 BR BR112020007751-8A patent/BR112020007751A2/pt unknown
- 2018-10-25 US US16/757,959 patent/US11981738B2/en active Active
- 2018-10-25 EP EP18871516.3A patent/EP3700571A4/en active Pending
- 2018-10-25 CN CN201880083063.4A patent/CN111836642A/zh active Pending
- 2018-10-25 JP JP2020523427A patent/JP7433222B2/ja active Active
-
2023
- 2023-11-10 JP JP2023192144A patent/JP2024023278A/ja not_active Withdrawn
-
2024
- 2024-03-22 US US18/613,372 patent/US20240287196A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110050000B (zh) | 含有TGF-β受体的融合蛋白及其医药用途 | |
| JP2019515676A5 (enExample) | ||
| JP5726731B2 (ja) | Ｆｇｆ−ｒ４受容体特異的拮抗薬 | |
| KR101699432B1 (ko) | 섬유아세포성장인자수용체 ２에 대한 모노클로날 항체 | |
| US8841424B2 (en) | Humanized AXL antibodies | |
| JP2021510141A (ja) | Ｉｇおよびｉｔｉｍドメインを持つｔ細胞免疫受容体（ｔｉｇｉｔ）に対する抗体およびその使用 | |
| TW202037603A (zh) | 異二聚免疫球蛋白 | |
| KR20180081606A (ko) | 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제 | |
| JP6931750B2 (ja) | 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法 | |
| JP2024026159A5 (enExample) | ||
| JP2021500895A5 (enExample) | ||
| JP2019513015A5 (enExample) | ||
| TW202229347A (zh) | 抗cd93之構築體及其用途 | |
| TW202210515A (zh) | 抗ｃｄ３９之構築體及其用途 | |
| JP7755062B2 (ja) | 新規抗ｌ１ｃａｍ抗体 | |
| EP4083068A9 (en) | Anti-ngf antibody and antigen-binding fragment thereof, preparation method thererofr, and application thereof | |
| EP3401330A1 (en) | Antibody inhibiting binding between vegf and nrp1 | |
| IL295979A (en) | Anti-cd36 antibodies and their use for cancer treatment | |
| AU2014246658B2 (en) | Antibodies against human RYK and uses therefor | |
| KR20200118409A (ko) | 암을 치료하기 위한 항-프로가스트린 항체와 면역치료 사이의 병용 치료 | |
| TW202339799A (zh) | 使用抗人類ｇｐｖｉ抗體抑制血小板凝集 | |
| TWI820618B (zh) | 抗TrkA抗體或其抗原結合片段、其製備方法和應用 | |
| US20240026019A1 (en) | Anti-tnfr2 antibody and use thereof | |
| JP7756686B2 (ja) | ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用 | |
| WO2021058735A1 (en) | Cancer treatment with anti-met antibody compositions |